Category Archives: Cell Therapy

UVA Children's Daniel "Trey" Lee, MD, is a pioneer in CAR T-cell immunotherapy.

New research from UVA Cancer Center and UVA Childrens Hospital could enable CAR T-cell immunotherapy to treat two forms of brain cancer that are now almost inevitably fatal. The discovery could lead to better treatments for other solid tumors as well.

The new research identifies vulnerabilities on solid tumors, including the brain tumors glioblastoma anddiffuse intrinsic pontine glioma (DIPG), that CAR T-cell immunotherapy could attack. Both of these brain tumors lack effective treatments. Only 6.8% of patients with glioblastoma survive five years after diagnosis; children with DIPG live, on average, only nine months after diagnosis despite intensive brain radiation and chemotherapy.

Researchers have struggled for decades to find new therapies to treat these cancers.Our work strongly suggests that CAR T cells could be highly active in treating glioblastoma and DIPG, said UVA researcher Daniel Trey Lee, MD, a pioneer in the field of CAR T-cell immunotherapy. This CAR T-cell therapy could be a game-changer for deadly brain tumors, much like a different CAR T-cell product shifted the paradigm for how we treat patients with relapsed leukemia and lymphoma.

Chimeric antigen receptor (CAR) T-cell therapy weaponizes our natural immune cells to make them more effective cancer killers. It extracts a small number of white blood cells called T cells from a patients blood, then genetically modifies them to kill cancer. Those cells are then infused back into the patient, where they replicate into a vast army of cancer killers. The entire process takes about two weeks, as opposed to other processes that can take months.

CAR T-cell immunotherapy has had significant success in battling blood cancers, but it has been less effective against solid tumors. Lees new finding could enhance its ability to target these tumors that now resist CAR T-cell treatment.

His new work identifies specific targets on glioblastoma and DIPG cells that the immunotherapy could exploit. When tested in mice, the approach was very effective the tumors shrank or disappeared, and the weaponized immune cells proved long-lasting. The approach also avoided side effects that have previously hampered its use in people.

Particularly notable was the approachs effectiveness againstDIPG, a cancer that threads itself through the brain, making it extremely hard to treat. Lees immunotherapy approach shrank thetumors and improved survival among lab mice. The scientists note that the cancers invasive nature likely will continue to pose a challenge, especially when the cancers tentacles extend into vital areas of the brain, but the researchers were encouraged by the promising results.

Many solid tumors share the same vulnerabilities Lees team identified in glioblastoma andDIPG. That suggests the results could have wider applications for solid tumors.

We have already begun to see if we can use this same therapy to treat other tumors, like melanoma, breast cancer and the pediatric muscle tumor rhabdomyosarcoma, in the lab, said Lee, a pediatric oncologistat UVA Childrens and UVA Cancer Center. My team in the lab is working incredibly hard to understand how we can bring new and safer CAR T-cell therapies to the citizens of Virginia and beyond. Our findings in brain tumors represent a huge leap forward in doing just that, but there is much more work to be done.

While the new discovery has shown exciting promise, significantly more research will be needed before it can be translated into better treatments forpatients. This type of cutting-edge researchis an urgent mission of UVA Cancer Center, which is one of only 52 cancer centers in the country to be designated as a Comprehensive Cancer Center by the National Cancer Institute (NCI).The designationrecognizes elite cancer centers with the most outstanding cancer research and treatment programs in the nation.

UVA Cancer Center is the only Comprehensive Cancer Center in Virginia.

Lee and his team havepublished their latest findings in the Journal of Immunotherapy for Cancer. The research team consisted ofDustin A. Cobb,Jacopo de Rossi,Lixia Liu,Erin An andLee. Lee serves as a consultant to Juno Therapeutics/BMS, Harpoon Therapeutics and Amgen, and his spouse is an employee of Karyopharm Therapeutics. In addition, he and Cobb have a patent application pending based on the approach. UVA receives clinical trial funding from Kite Pharma/Gilead.

The work was funded by the Childhood Brain Tumor Foundation, The V Foundation for Cancer Research and UVAs Strategic Investment Fund.To keep up with the latest medical research news from UVA, subscribe to theMaking of Medicineblog

More here:
Discovery Points to Better Treatments for Brain Tumors - UVA Health Newsroom

New data show that after 4 years of treatment, 78.8% of patients who continuously received ofatumumab achieved no evidence of disease activity-3 (NEDA-3) compared to 51.8% of those who switched from teriflunomide to ofatumumab.

Novartis announced new data from the phase 3 ASCLEPIOS 1/2 trial and the ALITHIOS open-label extension trial showing that continuous treatment with ofatumumab (Kesimpta) for relapsing forms of multiple sclerosis (RMS) significantly increased the odds of achieving no evidence of disease activity (NEDA-3) compared to switching from teriflunomide.1 The data were presented at the European Academy of Neurology Annual Meeting held in Vienna, Austria.1

Early initiation of high-efficacy therapies for the treatment of relapsing multiple sclerosis has been shown to improve long-term outcomes versus escalating from lower efficacy therapies, researcher Ludwig Kappos, MD, from University Hospital Basel, said in a statement. NEDA-3 is an important endpoint for physicians to consider when deciding to initiate high efficacy therapy. With this latest data from ALITHIOS we can clearly see the benefit of starting [ofatumumab] early versus switching to it later from teriflunomide.1

The data show that after 4 years of treatment, 78.8% of those who continuously received ofatumumab achieved NEDA-3, which was defined as having no MS relapses and no disability worsening and no MRI activity when compared to only 51.8% of those who switched from teriflunomide to ofatumumab in the extension phase.1

The results build on previously presented efficacy data from both studies, demonstrating sustained differences in cumulative responses, MRI lesion activity, and the risk of disability worsening between those who were continuously treated with ofatumumab than those who were switched at a later date.1

Ofatumumab is currently approved for treatment of RMS in the United States, European Union, United Kingdom, Canada, China, Switzerland, Singapore, Australia, Japan, Argentina, United Arab Emirates, Albania, and India.

According to the Mayo Clinic, MS is a disabling disease of the central nervous system, including the brain and the spinal cord. The cause of MS is unknown, and it is considered an autoimmune disease in which the bodys immune system attacks its own tissues. The immune system malfunction destroys the fatty substances that coats protective nerve fibers.2

Individuals with MS can experience muscle stiffness, muscle spasms, paralysis, problems with bladder, bowel, or sexual functions, mental changes, depression, and epilepsy.2

Ofatumumab is a targeted, precisely dosed, and delivered B-cell therapy that provides the flexibility of self-administration for adults with RMS and is designed to be delivered subcutaneously by a once monthly injection.1

Reference

1. New Novartis extension phase data show nearly 80% of RMS patients treated with Kesimpta (ofatumumab) had no evidence of disease activity (NEDA-3). Novartis. News release. June 27, 2022. Accessed June 29, 2022. https://www.novartis.com/news/media-releases/new-novartis-extension-phase-data-show-nearly-80-rms-patients-treated-kesimpta-ofatumumab-had-no-evidence-disease-activity-neda-3

2. Mayo Clinic. Multiple sclerosis. Updated January 7, 2022. Accessed June 29, 2022. https://www.mayoclinic.org/diseases-conditions/multiple-sclerosis/symptoms-causes/syc-20350269

Read the original:
Treatment with Ofatumumab Increases Number of Patients Who Achieve No Evidence of Disease Activity for MS - Pharmacy Times

New Cleveland Clinic research has uncovered key information about cellular interaction between tumor cells and normal tissue, providing better understanding of how therapeutic resistance develops.

In the study of drug resistance, researchers often try to understand the fitness of cells that have specific mutations in the presence of a drug in a laboratory setting, explained Jacob Scott, M.D., D.Phil., radiation oncologist and head of Cleveland Clinics Theory Division in the Lerner Research Institute Department of Translational Hematology and Oncology Research. But the reality is more complex, because tumor cells dont exist in a vacuum; instead, they co-exist in a complex, heterogeneous mixture of other tumor cells and normal tissues an interacting ecology.

Jacob Scott, M.D., D.Phil.

With approximately 90% of cancer deaths attributed to treatment-resistant disease, these cellular interactions, also known as evolutionary games, have high stakes.

In their latest study published July 1 in Science Advances, Dr. Scott and his collaborators used an assay they previously developed to directly measure those interactions in a simplified tumor environment consisting of drug-resistant non-small cell lung cancer cells and drug-sensitive precursor (ancestor) cells.

Cells resistant to the metastatic non-small cell lung cancer treatment gefitinib were derived from existing lung cancer cells by continual treatment with gefitinib over six months, and grown in an in vitro co-culture experiment with their sensitive ancestors. Cellular growth dynamics were assessed with and without gefitinib.

We cultured the two groups of cells together in different starting fractions and we measured how their growth changed depending on how much of each group was mixed together, explained Jeff Maltas, Ph.D., a postdoctoral researcher at Cleveland Clinic and co-lead author on the study.

The researchers found that the fitness of the resistant typeof cellchanges drastically depending on the composition of the mixture. Experiments revealed that the resistant population was outcompeted by the ancestral line at all studied population frequencies in the absence of therapy, pointing to complete competitive exclusion of the resistant populationand a cost of resistance. When gefitinib was added, there was a complete reversal of this effect, and the resistant clone was able to outcompete the sensitive ancestor.

This changing growth dynamics between treatment-resistant and treatment-sensitive cells could not be detected by standard assays available to date and suggests a novel mechanism by which resistant cells persist in the absence of treatment.

This paper highlights the need to understand and directly measure those ecological interactions that come from being around other cell types, Dr. Scott said. Thats something were doing here thats fundamentally different.

Dr. Scott notes that although these latest findings cannot be directly extrapolated to clinical scenarios, they do raise important questions with potentially significant implications on clinical research and trial design. In broader terms, could patients benefit from taking a break from medication to allow the maintenance of a critical treatment-sensitive population of tumor cells? And, could treatment regimens consisting of on-treatment and off-treatment periods allow for better control of cancer cell growth and, in the long term, prolong the lives of patients?

One of the most exciting parts of this paper is the opportunity for clinical advances that it highlights, Dr. Scott said. The design and testing of dynamic treatment regimens that could keep cancer cells in check over the long term may be the next translational application of these important findings.

Cleveland Clinics Theory Division conducts cancer research to develop and make available novel diagnostic tools, targeted therapies and clinical trials for direct use in patient care.

Go here to read the rest:
Cleveland Clinic Researchers Shed New Light on Importance of Cellular Interactions in Targeted Therapy Resistance in Lung Cancer - Cleveland Clinic...

HOUSTON, June 27, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (Alaunos or the Company) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company, today announced that the Company has extended its Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), an institute of the National Institutes of Health, using the Alaunos Sleeping Beauty technology through January 2025.

Under the terms of the CRADA, the NCI will work to generate proof of concept utilizing the Companys proprietary non-viral Sleeping Beauty technology for personalized TCR-T cell therapy. In this setting, T-cell receptors (TCRs) that react to the patients tumor will be identified from the patient and used to generate a TCR-T cell therapy. This approach could potentially apply to a wide range of solid tumor cancer patients. Alaunos believes that the non-viral Sleeping Beauty technology could rapidly and cost effectively produce safe and potent TCR-T cell therapies without the complexity of geneediting or viral approaches. Research conducted under the CRADA will be led by Steven A. Rosenberg, M.D., Ph.D., Chief of the Surgery Branch at the NCI's Center for Cancer Research.

We are privileged to extend the productive collaboration with Dr. Rosenberg, a cell therapy pioneer. Dr. Rosenberg and the NCI are working to develop personalized cancer therapies using our novel TCR-T cell platform, commented Kevin S. Boyle, Sr., Chief Executive Officer of Alaunos. Our collaboration reinforces our commitment to improving the lives of cancer patients with solid tumors. We look forward to continuing our collaborating with Dr. Rosenberg and his team to generate proof of concept in this personalized TCR-T approach.

Drew Deniger, Ph.D., Vice President, Research & Development at Alaunos added, Having worked alongside Dr. Rosenberg for many years, I am confident that his team at the NCI will be successful in developing personalized TCR-T therapies using our non-viral Sleeping Beauty technology. As the worlds experts in Sleeping Beauty, we believe that our non-viral means of adding the TCR to T cells is well suited for a personalized approach, with potential to further increase the addressable population for TCR-T therapies.About Alaunos TherapeuticsAlaunos is a clinical-stage oncology-focused cell therapy company, focused on developing T-cell receptor (TCR) therapies based on its proprietary, non-viral Sleeping Beauty gene transfer technology and its TCR library targeting shared tumor-specific hotspot mutations in key oncogenic genes including KRAS, TP53 and EGFR. The Company has clinical and strategic collaborations with The University of Texas MD Anderson Cancer Center and the National Cancer Institute. For more information, please visit http://www.alaunos.com.

Forward-Looking Statements Disclaimer This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts, and in some cases can be identified by terms such as may, will, could, expects, plans, anticipates, believes or other words or terms of similar meaning. These statements include, but are not limited to, statements regarding the Company's business and strategic plans, the anticipated outcome of preclinical and clinical studies by the Company or its third-party collaborators, the Company's cash runway, and the timing of the Company's research and development programs, including the anticipated dates for filing INDs, enrolling and dosing patients in and the expected timing for announcing preclinical data and results from the Companys clinical trials. Although the management team of Alaunos believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Alaunos, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include, among other things, changes in the Companys operating plans that may impact its cash expenditures; the uncertainties inherent in research and development, future clinical data and analysis, including whether any of Alaunos product candidates will advance further in the preclinical research or clinical trial process, including receiving clearance from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies to conduct clinical trials and whether and when, if at all, they will receive final approval from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies and for which indication; the strength and enforceability of Alaunos intellectual property rights; and competition from other pharmaceutical and biotechnology companies as well as risk factors discussed or identified in the public filings with the Securities and Exchange Commission made by Alaunos, including those risks and uncertainties listed in the most recent periodic report filed by Alaunos with the Securities and Exchange Commission. Alaunos is providing this information as of the date of this press release, and Alaunos does not undertake any obligation to update or revise the information contained in this press release whether as a result of new information, future events, or any other reason.

Investor Relations Contact:Alex LoboStern Investor RelationsAlex.lobo@sternir.com

Read the original:
Alaunos Therapeutics and the National Cancer Institute Extend Cooperative Research and Development Agreement for Development of Personalized TCR-T...

LONDON, June 30, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced the appointment of James Taylor as Chief Business Officer and Cassian Yee, MD to its Scientific Advisory Board (SAB), effective July 1, 2022.

James brings over 25 years of value-creating deal experience that includes global platform and asset deals for pharmaceutical and biotechnology companies. Most recently, he was Chief Business Officer at Sosei Heptares, where he completed a major collaboration with Neurocrine Biosciences for a Phase II-ready M4 agonist for schizophrenia, and led deals with Genentech, Takeda, AbbVie, GSK, Verily, Aditum and Biohaven Pharmaceuticals. Prior to this, James was a senior director at GSK where he led deals with GlycoVaxyn, Novartis, Pfizer, Biological E and consulted for Galvani Bioelectronics, the GSK/Google joint venture. He has held executive management roles at AstraZeneca, Summit Therapeutics and Cellzome.

Achilles has pioneered clonal neoantigen-targeted therapy and AI-powered bioinformatics, offering the potential to unlock therapeutic capabilities that I believe will have a tremendous impact for patients, commented James Taylor, incoming Chief Business Officer at Achilles Therapeutics. I look forward to exploring strategic partnerships to maximize the value of precision T cell therapies and platform technologies for the treatment of solid tumors.

The Company has also expanded its Scientific Advisory Board with the addition of Cassian Yee, MD. Dr. Yee is a professor in the department of melanoma medical oncology and the department of immunology at The University of Texas MD Anderson Cancer Center, as well as director of the solid tumor cell therapy program at MD Anderson. He is a highly regarded immuno-oncology leader, and notable pioneer in the field of adoptive cellular therapy.

I am delighted to work closely with the team at Achilles as their precision T cell therapies further advance in the clinic, said Cassian Yee, MD, Director, Department of Solid Tumor Cell Therapy Program, Division of Center for Cancer Immunology Research, MD Anderson Cancer Center. I believe the neoantigen field is poised to make significant advances in the treatment of late-stage solid tumors and Achilles novel platform and modality can be part of that evolution.

About Achilles TherapeuticsAchilles is a clinical-stage biopharmaceutical company developing precision T cell therapies targeting clonal neoantigens: protein markers unique to the individual that are expressed on the surface of every cancer cell. The Company has two ongoing Phase I/IIa trials, the CHIRON trial in patients with advanced non-small cell lung cancer (NSCLC) and the THETIS trial in patients with recurrent or metastatic melanoma. Achilles uses DNA sequencing data from each patient, together with its proprietary AI-Powered PELEUS bioinformatics platform, to identify clonal neoantigens specific to that patient, and then develop precision T cell-based product candidates specifically targeting those clonal neoantigens.

Investors:Achilles TherapeuticsLee M. Stern, VP, IR & External Communicationsl.stern@achillestx.com

LifeSci AdvisorsJohn Mullalyjmullaly@lifesciadvisors.com

Media:Consilium Strategic CommunicationsMary-Jane Elliott, Sukaina Virji, Melissa Gardiner+44 (0) 203 709 5000achillestx@consilium-comms.com

Read more here:
Achilles Therapeutics Appoints James Taylor as Chief Business Officer and Cassian Yee, MD to Scientific Advisory Board - GlobeNewswire

When you're an oncologist and clinical trialist who finds yourself at the epicenter of a global health crisis, what do you do? Ajai Chari, MD, professor of medicine and the director of clinical research in the multiple myeloma (MM) program at the Icahn School of Medicine at Mount Sinai in New York, NY, saw an opportunity to contribute from the earliest days of the COVID-19 pandemic.

Even as New York City recorded nearly 25% of US deaths from COVID-19 in spring 2020 and the rest of the world watched in horror as the city set up makeshift morgues in refrigerated trucks,1,2 Chari spearheaded an international clinical study on behalf of the International Myeloma Society (IMS) to gather the initial data and perform the f irst large-scale analysis of patients with MM who contracted COVID-19.3

Charis longtime mentor and colleague Sundar Jagannath, MBBS, director of the Center of Excellence for Multiple Myeloma at Mount Sinai, believes his mentees work on this study sums up Chari very well. It was an honor [that Chari was] chosen to lead the IMSs study and it shows that he is highly respected and well thought of in the international myeloma community, Jagannath said. He is devoted to his patients and his trainees and is extraordinarily detail-oriented in everything he does.

This fall, Chari will turn that attention to detail to cochairing the 40th Annual CFS: Chemotherapy Foundation Symposium Innovative Cancer Therapy for Tomorrow. Physicians Education Resource, LLC (PER) is hosting the 3-day event November 9 to 11 as a hybrid meeting featuring live, interactive presentations in New York, NY, along with a virtual option.

When Chari sat down recently with OncologyLive to discuss current trends in therapeutics in MM, he started with a story to illustrate just how quickly the treatment landscape is changing. In 2018, he discussed hospice with a patient with advanced MM refractory to all available therapies and chronic kidney dysfunction that made it difficult to enroll him in nearly all clinical trials. Fortunately, he was able to participate in one study. Four years later he is in a stringent complete remission and in a bit of an existential crisis because he didnt think hed be alive today, Chari said. This case highlights the unprecedented pace of myeloma research in the last few years.

Charis patient joined the phase 2 STORM trial (NCT02336815), which evaluated the combination of oral selinexor (Xpovio) plus low-dose dexamethasone in patients with refractory heavily pretreated MM. The patient saw significant clinical improvements, including in his renal function, enabling him to join other clinical trials. When the FDA approved selinexor for patients with MM in 2019,4 the patient was able to receive the therapy again in combination with other MM agents. After his disease went into remission again, this patient has now received 2 different T-cellredirection therapies when those remissions ended.

Chari contrasts the current regulatory environment with that of even a few years ago. Historically, in multiple myeloma, to receive accelerated approval for a new drug for patients with an unmet need (ie, those who had exhausted all available therapies), you needed a 20% to 30% response rate for 3 to 4 months. Now we have game-changing T-cellredirecting therapies, such as CAR [chimeric antigen receptor] T-cell therapies and bispecific antibodies, he explained. These agents have shown outstanding results, blowing those previous numbers out of the water. T-cellredirection therapies are now giving anywhere from 60% to 100% response rates that are lasting upward of 9 months to we dont even know how long, because theyre so durable.

Even as new MM therapies receive approval, areas of unmet need remain. The definition of unmet need in myeloma is constantly changing as the drugs get better and better, but we have much more work left to do, Chari said.

Current areas of unmet need include as follows:

Although many of these needs will ultimately be tackled by new therapeutics, sometimes these challenges can be addressed by refining standards of care. This is one of Charis particular strengths, said Hearn Jay Cho, MD, PhD, chief medical officer of the Multiple Myeloma Research Foundation and associate professor of medicine at the Icahn School of Medicine at Mount Sinai. He cited a recent phase 2 study (NCT02176213) from Chari and colleagues that examined a regimen combining pomalidomide (Pomalyst), cyclophosphamide, and dexamethasone in patients with relapsed/refractory MM (RRMM).5

Chari and colleagues hypothesized that daily dosing of oral cyclophosphamide would yield good results while meshing well with oral formulations of the other 2 drugs. In 33 evaluable patients, the overall response rate (ORR) was 73%, the median progression-free survival (PFS) was 13.3 months (95% CI, 7.9-not reached [NR]) and the median overall survival (OS) was 57.2 months (95% CI, 42.2-NR). The investigators concluded that adding daily cyclophosphamide to the regimen is a cost-effective oral strategy with encouraging PFS. All-oral treatment options that are well tolerated are especially important for older patients or those who cant travel to receive care frequently, Cho said. This is a great example of Chari applying a creative solution to an unmet need in the myeloma field.

Since 2010, when Chari and Jagannath joined Mount Sinai, Chari has served as principal investigator on 36 clinical trials and as a co-investigator on 68 additional trials. Whats more, he has developed 6 investigator-initiated clinical trials with a cumulative $4.3-million budget and worked on virtually every recent FDA approval for MM therapies. Chari offered a snapshot of key therapeutic advances in MM, all of which will be discussed at the CFS meeting.

One of the most stellar achievements of the past decade in myeloma has been the development of CAR T-cell therapies, in which patients own T cells are collected and genetically modified prior to reinfusion. First came idecabtagene vicleucel (ide-cel; Abecma), a B-cell maturation antigen (BCMA)directed CAR T-cell therapy that received FDA approval in March 2021.6

This approval covers adult patients with RRMM who have received 4 or more prior lines of therapy, including an anti-CD38 monoclonal antibody (mAb), a proteasome inhibitor (PI), and an immunomodulatory (IMiD) agent. Approval was based on the phase 2 KarMMa trial (NCT03361748) in which 33% of treated patients had a complete response (CR).7 Investigators confirmed minimal residual disease (MRD)negative status in 33 patients, representing 26% of all 128 patients who were treated and 79% of the 42 patients who had a CR or better. After a median follow-up of 13.3 months, the ORR among all treated patients was 73% (95% CI, 66%-81%).

In February 2022, the FDA approved ciltacabtagene autoleucel (cilta-cel; Carvykti), also a BCMA-directed CAR T-cell therapy, for patients with RRMM after 4 or more prior lines of therapy, including a PI, an IMiD, and an anti-CD38 mAb.8 The decision was based on findings from the phase 1/2 CARTITUDE-1 trial (NCT03548207), an open-label, multicenter study that tested the treatment in 97 patients with RRMM. The ORR was 97.9% (95% CI, 92.7%-99.7%). Among 95 responders, the median duration of response (DOR) was not reached.8,9

Both ide-cel and cilta-cel have been game-changers for our patients in that they are nearly one-and-done therapies. Patients who used to get continuous therapy indefinitely get this one intervention and then enjoy treatment-free intervals that didnt seem possible not long ago, Chari said. Their success has caught us by surprise because usually patients with myeloma have pretty beat-up immune systems with 5 or 6 years of chemotherapy and transplant behind them, so its remarkable that these T cells even work, let alone work this well.

Chari is mindful of the CAR T-cell therapies significant shortcomings, including limited availability from manufacturers, supply chain challenges, and high price tags. There are newer forms of CAR T cells under development that are looking at shorter manufacturing times [due to] an off-the-shelf design, he said.

Bispecific antibodies are another novel therapy on the horizon in MM. Although no such agents have received FDA approval for MM so far, many therapeutics appear promising. In the MM space, there are at least 12 bispecific antibodies undergoing clinical testing, and additional agents are in preclinical development, Chari and colleagues at Mount Sinai wrote in a recent clinical review in Blood Cancer Discovery.10 They said this class of drugs likely will become an important addition to the field, particularly for triple-class refractory, heavily treated disease.

Two of these bispecifics, talquetamab (JNJ64407564) and teclistamab (JNJ-64007957), have been in the spotlight at recent conferences. Chari has been instrumental in studies of both therapies.

Talquetamab is an investigational T-cellredirecting bispecific antibody targeting both GPRC5D, a novel MM target, and CD3, a T-cell receptor. MonumenTAL-1 (NCT03399799), a phase 1 first-in-human dose-escalation study, showed that talquetamab monotherapy administered subcutaneously (sub-Q) evoked high overall responses that deepened over time at 2 different dosing schedules in patients with triple-class and penta-drug refractory disease, according to findings presented at the 2022 American Society of Clinical Oncology Annual Meeting (2022 ASCO).11

With a median follow-up of 13.2 months, the ORR was 70.0% among 30 patients treated with talquetamab at 405 g/kg weekly, including a very good partial response (VGPR) in 56.7% of participants. The ORR was 63.6%, including a VGPR of 56.8%, among 44 patients who received talquetamab at 800 g/kg every other week after a median follow-up of 7.7 months. The median DOR was 10.2 months (95% CI, 3.0-not estimable [NE]) among participants who responded to weekly dosing and 13.0 months (95% CI, 5.3-NE) for the biweekly dosing. The most common nonhematologic adverse events (AEs) were cytokine release syndrome (CRS), skin-related AEs, and dysgeusia, mostly of grade 1 or 2 severity. Grade 3/4 AEs included 1 patient with CRS at the weekly dosing level and 1 with skin-related reactions with biweekly dosing.

Talquetamab monotherapy is being evaluated at both dosing levels in the phase 2 multicohort TALMMY1001-PT3 study (NCT04634552), which seeks to enroll an estimated 320 participants with RRMM after 3 or more prior lines of therapy. Additionally, the agent is undergoing testing in combination with other therapies in phase 1 studies.11

Chari also is an investigator on the multicohort phase 1b TRIMM-2 study (NCT04108195) testing daratumumab with hyaluronidase-fihj (Darzalex Faspro), a sub-Q formulation of daratumumab, plus talquetamab or teclistamab with or without pomalidomide (Pomalyst).12,13

Sub-Q daratumumab is itself a relatively novel form of the anti-CD38 mAb; the FDA initially approved the formulation in May 2020 as monotherapy and in combination for several indications held by the intravenous (IV) form of daratumumab (Darzalex).14 Teclistamab is a bispecific antibody that targets both CD3 expressed on the surface of T cells and BCMA expressed on the surface of myeloma cells.15

During the 2022 European Hematology Association Annual Meeting, investigators presented updated findings for 51 evaluable patients who received talquetamab plus sub-Q daratumumab across dosing levels during TRIMM-2. At a median follow-up of 5.1 months across dosing cohorts, the ORR was 80.4%, including a CR or better in 29.4% and a VGPR or better in 62.7%. Additionally, the ORR was 77.3% among patients (34 of 44) with prior exposure to an anti-CD38 mAb and 72% among participants (18 of 25) with prior BCMA-targeted treatment. The safety profile of the combination was comparable with what has been reported with each agent separately.16

At 2022 ASCO, investigators reported findings for the TRIMM-2 cohort that received teclistamab plus sub-Q daratumumab. In 51 evaluable patients, the ORRs were 75.0% (15 of 20 patients), 74.1% (20 of 27 patients), and 100% (4 of 4 patients) at teclistamab dosing levels of 1.5 mg/kg weekly, 3 mg/kg biweekly, and 3 mg/kg weekly, respectively. All patients received 1800 mg of sub-Q daratumumab with each cycle.17

Teclistamab also demonstrated efficacy as monotherapy in the phase 1/2 MajesTEC-1 trial (NCT03145181; NCT04557098), whose results were simultaneously presented at 2022 ASCO and published in the New England Journal of Medicine (NEJM). The ongoing study involves patients with RRMM who have received at least 3 lines of therapy, including an IMiD, a PI, and an anti-CD38 mAb. Patients were treated with a weekly sub-Q injection of teclistamab dosed at 1.5 mg/kg of body weight after receiving 2 step-up doses.15,18

Among 165 patients who received teclistamab, the ORR was 63.0% (95% CI, 55.2%-70.4%), with 39.4% having a CR or better and 58.8% having a VGPR or better at a median follow-up of 14.1 months. Overall, 26.7% (95% CI, 20.1%34.1%) tested negative for MRD. Among the 65 patients with a CR or better response, the MRD negativity rate was 46.0%. The median DOR was 18.4 months (95% CI, 14.9-NE). The median PFS was 11.3 months (95% CI, 8.8- 17.1). Median OS data were immature.

When it comes to novel therapies for MM, the research team at Mount Sinai has been particularly prolific. Weve been involved in almost every single drug thats been FDA approved in the last 10 to 15 years, Chari said.

The list includes belantamab mafodotin-blmf (Blenrep), an antibody-drug conjugate directed against BCMA that obtained FDA accelerated approval in August 2020 for patients with RRMM who have received at least 4 prior lines of therapy.19 The drug was the first approved agent to target BCMA, a cell-surface receptor broadly expressed on MM cells but not on naive and memory B cells. Chari was among the investigators on the pivotal phase 2 DREAMM-2 study (NCT03525678).20

Additionally, Chari was the first author on an article in the NEJM describing the findings of the STORM trial, which paved the way for the FDAs approval of selinexor in combination with dexamethasone for adults with RRMM who have received at least 4 prior therapies and whose disease is refractory to at least 2 PIs, at least 2 IMiDs, and an anti-CD38 mAb. Selinexor inhibits exportin 1, which enables nuclear export of cargo proteins such as tumor suppressor proteins and is overexpressed in MM.4,21

Meanwhile, the further development of sub-Q daratumumab also has been on Charis radar. Daratumumab is a workhorse of the MM treatment landscape. Initially approved in 2015 as monotherapy for double- or triple-refractory MM after at least 3 prior lines of therapy, the IV formulation of daratumumab now carries multiple indications for relapsed and newly diagnosed disease in combination with other agents such as bortezomib (Velcade), carfilzomib (Kyprolis), lenalidomide (Revlimid), and pomalidomide.22

The sub-Q formulation of daratumumab requires shorter administration time3 to 5 minutes compared with 7 hours for the first infusion of IV daratumumab, and with 3 to 4 hours for subsequent cyclesaccording to findings from the COLUMBA trial (NCT03277105). Clinical outcomes with the sub-Q version were noninferior to those with the IV format and there were fewer infusion-related reactions.23

Chari and colleagues demonstrated the efficacy of sub-Q daratumumab in several standard-of-care MM combination regimens in the phase 2 PLEIADES trial (NCT03412565).24 The study findings formed the basis for the FDAs approval of 3 indications for combination regimens incorporating the sub-Q format: with bortezomib, melphalan, and prednisone in patients with newly diagnosed MM who are ineligible for transplant; with lenalidomide/ dexamethasone for RRMM; and with carfilzomib/dexamethasone in RRMM.25

The PLEIADES study looked at various daratumumab combinations in the subcutaneous formulation, Chari said. Key takeaways were that subcutaneous daratumumab has efficacy and pharmacokinetics comparable with what you would expect based on monotherapy and IV combinations of the respective agents.

The plethora of novel therapies that have been introduced to the MM treatment paradigm in recent years has ignited debate about the future role of autologous stem cell transplant (ASCT).

Findings from the phase 3 MAIA study (NCT02252172) in patients with newly diagnosed MM who were not eligible for ASCT demonstrated that the addition of IV daratumumab to lenalidomide plus dexamethasone resulted in superior outcomes compared with a lenalidomide/dexamethasone combination.26

After a median follow-up of 56 months, the median PFS among patients who received daratumumab (n = 368) was not reached (95% CI, 54.8-NR) compared with 34.4 months (95% CI, 29.6-39.2) in participants (n = 369) treated with lenalidomide/dexamethasone alone (HR, 0.53; 95% CI, 0.43-0.66; P < .0001). Median OS was not reached in either group. The median age of participants was 73 years (range, 70-78) in the daratumumab-containing arm and 74 years (range, 70-78) in the control arm.26

Chari said the MAIA findings, published in Lancet Oncology in October 2021, represent a noteworthy advancement for older patients with MM. The problem with older patients in particular is that they dont always get to the umpteenth line of therapy, Chari said. Sometimes you get 1 or 2 shots [at effective treatment].

A median PFS not reached with nearly 5 years of follow-up for those who received daratumumab in MAIA is amazing, considering this is without ASCT in an older MM population, Chari said.

More recently, the MM community has been dissecting findings from the phase 3 DETERMINATION trial (NCT01208662), whose results were simultaneously presented at 2022 ASCO and published in the NEJM.27,28 This trial explored the question of whether ASCT improves outcomes for patients with newly diagnosed MM who are eligible for transplant and receive triple induction therapy with lenalidomide, bortezomib, and dexamethasone (RVd).

Investigators randomized patients (n = 357) to treatment with RVd for 2 to 3 cycles followed by RVd for 4 to 8 cycles or RVd plus melphalan and ASCT (n = 365) followed by RVd for 4 to 5 cycles. All patients were eligible for lenalidomide maintenance therapy until progression. The median age of patients was 57 years (range, 25-66) in the RVd-alone arm and 55 years (range, 30-65) in the RVd plus ASCT arm.

After a median follow-up of 76.0 months, the median PFS was significantly shorter in patients who received RVd alone at 46.2 months (95% CI, 38.1-53.7) than among participants treated with RVd plus ASCT at 67.5 months (95% CI, 58.6-NR). The risk of disease progression or death was 53% higher among those who did not receive ASCT (HR, 1.53; 95% CI, 1.23-1.91; P < .0001). However, 5-year OS, a key secondary end point, was similar between the 2 arms (HR, 1.10; adjusted 95% CI, 0.73-1.65; P = .99).

Chari expects the debate about the clinical utility of ASCT to continue for the foreseeable future. On the one hand, transplant is integral in the improvement of outcomes in patients with myeloma, especially globally, because its a relatively cost-effective standard, he said.

The benefit, however, favors younger patients, according to data from the National Cancer Institutes Surveillance, Epidemiology, and End Results (SEER) Program. If you look at Medicare SEER data, the patients whose survival has improved most are not the frail, older elderly, but the younger patients [who can tolerate transplant], Chari said.

Does transplant still have a role with all these amazing therapies? Chari continued. Many people want OS as a primary end point, but its nearly impossible to do that in large, randomized studies, given the innumerable and also ever-increasing number of salvage therapy options as well as the prohibitively long follow-up time that would be required for a disease where the median OS for some patients with MM is more than 10 years. So, theres this constant back-and-forth about the role of transplant, especially in newly diagnosed patients.

For his part, Chari remains dedicated to exploring ways to improve outcomes for patients with MM through better use of existing regimens and the development of novel therapies. Whats more gratifying than seeing people who are alive and in complete remission for years beyond where they thought they would be? You have patients who are bedridden or bed-bound and within a few months are back to their pre-myeloma quality of life because the therapeutics are so effective, and symptoms of myeloma can be so rapidly reversed. Its really gratifying.

Read more from the original source:
More Novel Therapies Are on the Horizon in Multiple Myeloma - OncLive

Over the last six decades, hematologists have made momentous strides in research, including the development of new, cutting-edge therapeutic technologies that have paved the way for remarkable advances in the treatment of many serious blood diseases,

NEW YORK (PRWEB) June 30, 2022

Mediaplanet today announces the launch of the print and digital campaign, Blood Health. With the increasing prevalence of people suffering from blood cancers and disorders, its never been more important to educate the public about the human bodys most valuable player and current challenges that patients, providers, and researchers face. This campaign will inspire action and encourage readers to educate themselves by engaging with compelling stories of patients; announcements of scientific and medical breakthroughs; and new therapeutic and diagnostic approaches to blood cancers, sickle cell disease, hemophilia and other blood and bleeding disorders.

Over the last six decades, hematologists have made momentous strides in research, including the development of new, cutting-edge therapeutic technologies that have paved the way for remarkable advances in the treatment of many serious blood diseases, writes Jane N. Winter, M.D., president of the American Society of Hematology (ASH) in an introduction article in the publication.

Some of these cutting-edge therapeutic technologies include advancements in CAR T-cell therapy, sickle cell trait testing, and integrated, global master clinical trials for childrens blood cancers. CAR T-cell therapy involves taking a persons immune cells from their blood, reprogramming the immune cells to target the patients blood cancer, and then returning these new guided missiles to the patient as a transfusion, writes Winter. Momentum in research for CAR T-cell therapies for children is growing as well, since it has the potential to cause fewer side effects than chemotherapy, which is one of the key challenges for pediatric blood cancers current standard of care.

This year marked 10 years since pioneer pediatric patient Emily Whitehead was successfully treated for her acute lymphoblastic leukemia (ALL) with CAR T-cell therapy at the Childrens Hospital of Philadelphia. The therapy saved Emilys life, and she is still cancer-free today. Readers can find her story, among many others, within the Blood Health campaign.

The print component of Blood Health is distributed within todays edition of USA Today in New York, Boston, Philadelphia, Chicago, Carolinas, Denver, Dallas, Houston, Kansas City, Nashville, Washington D.C., Baltimore, Pittsburgh, Cleveland, Detroit, Minneapolis, Cincinnati, St. Louis, Los Angeles, and surrounding areas with a circulation of approximately 150,000 copies and an estimated readership of 450,000. The digital component is distributed nationally through a vast social media strategy and across a network of top news sites and partner outlets. To explore the digital version of the campaign, visit: futureofpersonalhealth.com

This campaign was made possible with the support of the American Red Cross, American Society for Clinical Pathology, American Society of Hematology, AstraZeneca, Be the Match, the Emily Whitehead Foundation, Genentech, Jerry Rice, the Leukemia & Lymphoma Society, the MPN Research Foundation, TC BioPharm, and more.

About MediaplanetMediaplanet specializes in the creation of content marketing campaigns covering a variety of industries. We tell meaningful stories that educate our audience and position our clients as solution providers. Our unique ability to pair the right leaders with the right readers, through the right platforms, has made Mediaplanet a global content marketing powerhouse. Our award-winning stories have won the hearts of countless readers while serving as a valuable platform for brands and their missions. Just call us storytellers with a purpose. Please visit http://www.mediaplanet.com for more on who we are and what we do.

Contact:Shannon Ruggiero646-755-7962Shannon.ruggiero@mediaplanet.com

Share article on social media or email:

Read the rest here:
Mediaplanet Partners With Hematology Industry to Improve the Conversation Around Blood Health - PR Web

Smartphones, superglue, electric cars, video chat. When does the wonder of a new technology wear off? When you get so used to its presence that you dont think of it anymore? When something newer and better comes along? When you forget how things were before?

Whatever the answer, the gene-editing technology CRISPR has not reached that point yet. Ten years after Jennifer Doudna and Emmanuelle Charpentier first introduced their discovery of CRISPR, it has remained at the center of ambitious scientific projects and complicated ethical discussions. It continues to create new avenues for exploration and reinvigorate old studies. Biochemists use it, and so do other scientists: entomologists, cardiologists, oncologists, zoologists, botanists.

Cathie Martin, a botanist at the John Innes Centre in Norwich, England, and Charles Xavier, founder of the X-Men superhero team: They both love mutants.

But while Professor X has an affinity for superpowered human mutants, Dr. Martin is partial to the red and juicy type. We always craved mutants, because that allowed us to understand functionality, Dr. Martin said of her research, which focuses on plant genomes in the hopes of finding ways to make foods especially tomatoes in her case healthier, more robust and longer lasting.

When CRISPR-Cas9 came along, one of Dr. Martins colleagues offered to make her a mutant tomato as a gift. She was somewhat skeptical, but, she told him, I would quite like a tomato that produces no chlorogenic acid, a substance thought to have health benefits; tomatoes without it had not been found before. Dr. Martin wanted to remove what she believed was the key gene sequence and see what happened. Soon a tomato without chlorogenic acid was in her lab.

Instead of looking for mutants, it was now possible to create them. Getting those mutants, it was so efficient, and it was so wonderful, because it gave us confirmation of all these hypotheses we had, Dr. Martin said.

Most recently, researchers at Dr. Martins lab used CRISPR to create a tomato plant that can accumulate vitamin D when exposed to sunlight. Just one gram of the leaves contained 60 times the recommended daily value for adults.

Dr. Martin explained that CRISPR could be used across a broad spectrum of food modifications. It could potentially remove allergens from nuts and create plants that use water more efficiently.

I dont claim that what we did with vitamin D will solve any food insecurity problems, Dr. Martin said, but its just a good example. People like to have something that they can hang on to, and this is there. Its not a promise.

Infectious Disease

Christian Happi, a biologist who directs the African Centre of Excellence for Genomics of Infectious Diseases in Nigeria, has spent his career developing methods to detect and contain the spread of infectious diseases that spread to humans from animals. Many of the existing ways to do so are costly and inaccurate.

For instance, in order to perform a polymerase chain reaction, or PCR, test, you need to go extract RNA, have a machine thats $60,000 and hire someone who is specially trained, Dr. Happi said. Its both costly and logistically implausible to take this kind of testing to most remote villages.

Recently, Dr. Happi and his collaborators used CRISPR-Cas13a technology (a close relative of CRISPR-Cas9) to detect diseases in the body by targeting genetic sequences associated with pathogens. They were able to sequence the SARS-CoV-2 virus within a couple of weeks of the pandemic arriving in Nigeria and develop a test that required no on-site equipment or trained technicians just a tube for spit.

If youre talking about the future of pandemic preparedness, thats what youre talking about, Dr. Happi said. Id want my grandmother to use this in her village.

The CRISPR-based diagnostic test functions well in the heat, is quite easy to use and costs one-tenth of a standard PCR test. Still, Dr. Happis lab is continually assessing the accuracy of the technology and trying to persuade leaders in the African public health systems to embrace it.

He called their proposal one that is cheaper, faster, that doesnt require equipment and can be pushed into the remotest corners of the continent. This would allow Africa to occupy what I call its natural space.

Hereditary Illness

In the beginning there was zinc finger nuclease.

That was the gene-editing tool that Gang Bao, a biochemical engineer at Rice University, first used to try to treat sickle cell disease, an inherited disorder marked by misshapen red blood cells. It took Dr. Baos lab more than two years of development, and then zinc finger nuclease would successfully cut the sickle cell sequence only around 10 percent of the time.

Another technique took another two years and was only slightly more effective. And then, in 2013, soon after CRISPR was used to successfully edit genes in living cells, Dr. Baos team changed tack again.

From the beginning to having some initial results, CRISPR took us like a month, Dr. Bao said. The method successfully cut the target sequence around 60 percent of the time. It was easier to make and more effective. It was just amazing, he said.

The next challenge was to determine the side effects of the process. That is, how did CRISPR affect genes that werent being purposefully targeted? After a series of experiments in animals, Dr. Bao was convinced that the method would work for humans. In 2020 the Food and Drug Administration approved a clinical trial, led by Dr. Matthew Porteus and his lab at Stanford University, that is ongoing. And there is also hope that with CRISPRs versatility, it might be used to treat other hereditary diseases. At the same time, other treatments that have not relied on gene editing have had success for sickle cell.

Dr. Bao and his lab are still trying to determine all the secondary and tertiary effects of using CRISPR. But Dr. Bao is optimistic that a safe and effective gene-editing treatment for sickle cell will be available soon. How soon? I think another three to five years, he said, smiling.

Cardiology

It is hard to change someones heart. And thats not just because we are often stubborn and stuck in our ways. The heart generates new cells at a much slower rate than many other organs. Treatments that are effective in other parts of the human anatomy are much more challenging with the heart.

It is also hard to know what is in someones heart. Even when you sequence an entire genome, there are often a number of segments that remain mysterious to scientists and doctors (called variants of uncertain significance). A patient might have a heart condition, but theres no way to tie it definitively back to their genes. You are stuck, said Dr. Joseph Wu, director of the Stanford Cardiovascular Institute. So traditionally we would just wait and tell the patient we dont know whats going on.

But over the past couple of years, Dr. Wu has been using CRISPR to see what kind of effects the presence and absence of these befuddling sequences have on heart cells, simulated in his lab with induced pluripotent stem cells generated from the blood. By cutting out particular genes and observing the effects, Dr. Wu and his collaborators have been able to draw links between the DNA of individual patients and heart disease.

It will be a long time before these diseases can be treated with CRISPR, but diagnosis is a first step. I think this is going to have a big impact in terms of personalized medicine, said Dr. Wu, who mentioned that he found at least three variants of uncertain significance when he got his own genome sequenced. What do these variants mean for me?

Sorghum is used in bread, alcohol and cereal all over the world. But it hasnt been commercially engineered to the same degree as wheat or corn, and, when processed, it often isnt as tasty.

Karen Massel, a biotechnologist at the University of Queensland in Australia, saw quite a bit of room for improvement when she first started studying the plant in 2015. And because millions of people eat sorghum worldwide, if you make a small change you can have a huge impact, she said.

She and her colleagues have used CRISPR to try to make sorghum frost tolerant, to make it heat tolerant, to lengthen its growth period, to change its root structure we use gene editing across the board, she said.

Not only could this lead to more delicious and healthier cereal, but it could also make the plants more resistant to the changing climate, she said. But it is still no small task to accurately edit the genomes of crops with CRISPR.

Half the genes that we knock out, we just have no idea what they do, Dr. Massel said. The second we try to get in there and play God, we realize were a bit out of our depth. But, using CRISPR combined with more traditional breeding techniques, Dr. Massel is optimistic, despite being a self-described pessimist. And she hopes that further advances will lead to commercializing gene-edited foods, making them more accessible and more acceptable.

In 2012, a 6-year-old girl was suffering from acute lymphoblastic leukemia. Chemotherapy had been unsuccessful, and the case was too advanced for a bone-marrow transplant. There didnt seem to be any other options, and the girls physicians told her parents to go back home.

Instead, they went to the Childrens Hospital of Philadelphia, where doctors used an experimental treatment called chimeric antigen receptor (CAR) T-cell therapy to turn the girls white blood cells against the cancer. Ten years later, the girl is cancer free.

Since then, Dr. Carl June, a medical professor at the University of Pennsylvania who helped develop CAR T-cell therapy, and his collaborators, including Dr. Ed Stadtmauer, a hematologist-oncologist at Penn Medicine, have been working to improve it. That includes using CRISPR, which is the simplest and most accurate tool to edit T-cells outside the body. Dr. Stadtmauer, who specializes in dealing with various types of blood and lymph system cancers, said that the last decade or so has just seen a revolution of treatment of these diseases; its been rewarding and exciting.

Over the past couple of years, Dr. Stadtmauer helped run a clinical trial in which T-cells that underwent significant CRISPR editing were inserted into patients with treatment-resistant cancers. The results were promising.

Nine months into the trial the edited T-cells had not been rejected by the patients immune systems and were still present in the blood. The real benefit is that scientists now know that CRISPR-aided treatments are possible.

Even though its really sort of science fiction-y biochemistry and science, the reality is that the field has moved tremendously, Dr. Stadtmauer said. He added that he was less excited by the science than how useful CRISPR had become. Every day I see maybe 15 patients who need me, he said. Thats what motivates me.

More here:
The Many Uses of CRISPR: Scientists Tell All - The New York Times

The global Mobile Cardiac Telemetry Systems Market research report gives a comprehensive analysis of market size, market trends, and market growth prospects. This report also provides extensive information on the technology expenditure for the forecast period, which gives a unique view of the global Mobile Cardiac Telemetry Systems Market across multiple segments. The global Mobile Cardiac Telemetry Systems market report also helps consumers recognize market opportunities and challenges. This report includes the most current Mobile Cardiac Telemetry Systems market forecast research over the expected period. The global Mobile Cardiac Telemetry Systems market report provides extensive information on technological developments and market growth prospects based on regional landscapes. The Mobile Cardiac Telemetry Systems Market Report is also designed using advanced methodologies and includes a detailed analysis of the Mobile Cardiac Telemetry Systems marketplaces sales and providers.

Free Sample Report + All Related Graphs & Charts @ https://www.adroitmarketresearch.com/contacts/request-sample/1746?utm_source=Sujag01

Leading players of Mobile Cardiac Telemetry Systems Market including:

BioTelemetry Inc., Biotricity Inc., ScottCare, Welch Allyn, Medicomp Inc., Applied Cardiac Systems Inc., Preventice Solutions, iRhythm Technologies, Inc., Telerhythmics LLC

In addition to this, the report by Adroit Market Research has been designed through the complete surveys, primary research interviews, as well as observations, and secondary research. Moreover, the Mobile Cardiac Telemetry Systems market report introduced the market through several factors such as classifications, definitions, market overview, product specifications, cost structures, manufacturing processes, raw materials, and applications. Moreover, the study offers a complete analysis of the market size, segmentation, and market share. Additionally, the Mobile Cardiac Telemetry Systems report contains market dynamics such as market restraints, growth drivers, opportunities, service providers, stakeholders, investors, key market players, profile assessment, and challenges of the global market.

Further to this, the Mobile Cardiac Telemetry Systems market report by Adroit Market Research holistically touches upon well-orchestrated data sources and insightful factors about multiple manufacturers and market honchos working extensively in the Mobile Cardiac Telemetry Systems market. This report also entails supply chain nuances, financial data analysis, products & services records, core developments, as well as elaborate description on acquisitions & mergers, current & future growth probabilities trends, as well as advances, inclusive of technological sophistication, that carefully craft market players footprint in the global Mobile Cardiac Telemetry Systems market.

The market segmentation information in the research report is a combination of primary and secondary research methods. The report includes both a quantitative as well as qualitative analysis of target market evaluations over the forecasted period to show the economic potential of the global target market. The global Mobile Cardiac Telemetry Systems industry is covered in this report, which includes current and prospective market trends. This will help to determine the potential market investment for the Mobile Cardiac Telemetry Systems industry. The research report also includes an industry analysis and forecasts for the registered forecast period. In addition, the Mobile Cardiac Telemetry Systems Market Study provides comprehensive data about the opportunities, key driver, and restraining factor with the contact analysis.

Mobile Cardiac Telemetry Systems market Segmentation by Type:

NA

Mobile Cardiac Telemetry Systems market Segmentation by Application:

By Application (Lead-Based, Patch-Based) End Use (Hospitals, Cardiac Centers, Others)

The Mobile Cardiac Telemetry Systems Market Reports Key Highlights:

The Mobile Cardiac Telemetry Systems global market report provides a comprehensive qualitative and quantitative analysis that will provide insight into the industry. This Mobile Cardiac Telemetry Systems market insight includes data from influential participants such as marketers, business experts and investors. The Mobile Cardiac Telemetry Systems market reports objective is to provide a comprehensive perspective from all stakeholders for young marketers and entrepreneurs. Trends and drivers are discussed in the Mobile Cardiac Telemetry Systems Market Report The global Mobile Cardiac Telemetry Systems market report provides an overview of the global competitive environment. It provides information about the market, its share and revenue. The Mobile Cardiac Telemetry Systems Market Report identifies the major growth regions, with Asia Pacific leading during the forecast period.

Table of Content:

Chapter 1. Research ObjectiveChapter 2. Executive SummaryChapter 3. Strategic AnalysisChapter 4. Mobile Cardiac Telemetry Systems Market DynamicsChapter 5. Segmentation & StatisticsChapter 6. Market Use case studiesChapter 7. KOL RecommendationsChapter 8. Investment LandscapeChapter 9. Competitive IntelligenceChapter 10. Company ProfilesChapter 11. AppendixContinued

Do You Have Any Query Or Specific Requirement? Ask to Our Industry Expert @ https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/1746?utm_source=Sujag01

ABOUT US:

Adroit Market Research is an India-based business analytics and consulting company. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a markets size, key trends, participants and future outlook of an industry. We intend to become our clients knowledge partner and provide them with valuable market insights to help create opportunities that increase their revenues. We follow a code Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.

CONTACT US:

Ryan JohnsonAccount Manager Global3131 McKinney Ave Ste 600, Dallas,TX 75204, U.S.APhone No.: USA: +1.210.667.2421/ +91 9665341414

Read the rest here:
Stem Cell Therapy Market Overview by Advance Technology, Future Outlook 2028 Anterogen Co., Ltd., MEDIPOST Co., Ltd., Osiris Therapeutics, Inc. and...

New Jersey, United States This Cell Therapy And Tissue Engineering Market research examines the state and future prospects of the Cell Therapy And Tissue Engineering market from the perspectives of competitors, regions, products, and end Applications/industries. The Worldwide Cell Therapy And Tissue Engineering market is segmented by product and Application/end industries in this analysis, which also analyses the different players in the global and key regions.

The analysis for the Cell Therapy And Tissue Engineering market is included in this report in its entirety. The in-depth secondary research, primary interviews, and internal expert reviews went into the Cell Therapy And Tissue Engineering reports market estimates. These market estimates were taken into account by researching the effects of different social, political, and economic aspects, as well as the present market dynamics, on the growth of the Cell Therapy And Tissue Engineering market.

Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart) @https://www.verifiedmarketresearch.com/download-sample/?rid=12301

Key Players Mentioned in the Cell Therapy And Tissue Engineering Market Research Report:

BioCardia Inc., Betalin Therapeutics Ltd., MEDIPOST Co. Ltd., MaxCyte Inc., BioReliance Corporation

The Porters Five Forces analysis, which explains the five forces: customers bargaining power, distributors bargaining power, the threat of substitute products, and degree of competition in the Cell Therapy And Tissue Engineering Market, is included in the report along with the market overview, which includes the market dynamics. It describes the different players who make up the market ecosystem, including system integrators, middlemen, and end-users. The competitive environment of the Cell Therapy And Tissue Engineering marketis another major topic of the report. For enhanced decision-making, the research also provides in-depth details regarding the COVID-19 scenario and its influence on the market.

Cell Therapy And Tissue EngineeringMarket Segmentation:

Cell Therapy and Tissue Engineering Market, By Type

Cell Therapy Tissue Engineering Others

Cell Therapy and Tissue Engineering Market, By Application

Cell Defects Genetic Diseases Tissue Malignancy Neurodegenerative Disease Others

Inquire for a Discount on this Premium Report@ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=12301

Cell Therapy And Tissue Engineering Market Report Scope

Key questions answered in the report:

1. Which are the five top players of the Cell Therapy And Tissue Engineering market?

2. How will the Cell Therapy And Tissue Engineering market change in the next five years?

3. Which product and application will take a lions share of the Cell Therapy And Tissue Engineering market?

4. What are the drivers and restraints of the Cell Therapy And Tissue Engineering market?

5. Which regional market will show the highest growth?

6. What will be the CAGR and size of the Cell Therapy And Tissue Engineering market throughout the forecast period?

For More Information or Query or Customization Before Buying, Visit @ https://www.verifiedmarketresearch.com/product/cell-therapy-and-tissue-engineering-market/

Visualize Cell Therapy And Tissue Engineering Market using Verified Market Intelligence:-

Verified Market Intelligence is our BI-enabled platform for narrative storytelling of this market. VMI offers in-depth forecasted trends and accurate Insights on over 20,000+ emerging & niche markets, helping you make critical revenue-impacting decisions for a brilliant future.

VMI provides a holistic overview and global competitive landscape with respect to Region, Country, and Segment, and Key players of your market. Present your Market Report & findings with an inbuilt presentation feature saving over 70% of your time and resources for Investor, Sales & Marketing, R&D, and Product Development pitches. VMI enables data delivery In Excel and Interactive PDF formats with over 15+ Key Market Indicators for your market.

Visualize Cell Therapy And Tissue Engineering Market using VMI @ https://www.verifiedmarketresearch.com/vmintelligence/

About Us: Verified Market Research

Verified Market Research is a leading Global Research and Consulting firm that has been providing advanced analytical research solutions, custom consulting and in-depth data analysis for 10+ years to individuals and companies alike that are looking for accurate, reliable and up to date research data and technical consulting. We offer insights into strategic and growth analyses, Data necessary to achieve corporate goals and help make critical revenue decisions.

Our research studies help our clients make superior data-driven decisions, understand market forecast, capitalize on future opportunities and optimize efficiency by working as their partner to deliver accurate and valuable information. The industries we cover span over a large spectrum including Technology, Chemicals, Manufacturing, Energy, Food and Beverages, Automotive, Robotics, Packaging, Construction, Mining & Gas. Etc.

We, at Verified Market Research, assist in understanding holistic market indicating factors and most current and future market trends. Our analysts, with their high expertise in data gathering and governance, utilize industry techniques to collate and examine data at all stages. They are trained to combine modern data collection techniques, superior research methodology, subject expertise and years of collective experience to produce informative and accurate research.

Having serviced over 5000+ clients, we have provided reliable market research services to more than 100 Global Fortune 500 companies such as Amazon, Dell, IBM, Shell, Exxon Mobil, General Electric, Siemens, Microsoft, Sony and Hitachi. We have co-consulted with some of the worlds leading consulting firms like McKinsey & Company, Boston Consulting Group, Bain and Company for custom research and consulting projects for businesses worldwide.

Contact us:

Mr. Edwyne Fernandes

Verified Market Research

US: +1 (650)-781-4080UK: +44 (753)-715-0008APAC: +61 (488)-85-9400US Toll-Free: +1 (800)-782-1768

Email: sales@verifiedmarketresearch.com

Website:- https://www.verifiedmarketresearch.com/

Read the original:
Cell Therapy And Tissue Engineering Market Size, Scope and Forecast | BioCardia Inc., Betalin Therapeutics Ltd., MEDIPOST Co. Ltd., MaxCyte Inc.,...